23.08.2017 • NewsElaine BurridgeSamsungbiologics

Samsung Bioepis and Takeda in Biologics Pact

(c) molekuul_be/Shutterstock
(c) molekuul_be/Shutterstock

South Korean biopharmaceutical company Samsung Bioepis is taking its first step into novel drug development with an agreement to partner Japan’s Takeda Pharmaceutical. The move expands Samsung Bioepis’ business beyond creating biosimilars, which has been its focus since launching in 2012.

The companies will jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. Samsung Bioepis said the collaboration will combine its biologics development platform with Takeda’s drug development expertise. An initial focus will be to develop TAK-671, a treatment for severe acute pancreatitis.

“With novel biologics, we will look to bring medicines to treat unmet diseases by breaking down two major hurdles facing biologics development—cost overruns and time delays,” British newspaper, Financial Times quotes Samsung as saying.

Samsung is reported to be seeking more partnerships with other pharmaceutical and biotech companies.

An offshoot of conglomerate Samsung, which is best known for making electrical and electronic devices, Samsung Bioepis became the first company to launch a biosimilar version of Amgen’s blockbuster rheumatoid arthritis drug Enbrel in Europe last year. It has also gained approval in Europe and the US for Renflexis, its copy of Johnson & Johnson’s Remicade used to treat autoimmune diseases.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.